Text Size
Trial record 5 of 312 for:    Hemophilia: Clinical Trials
Previous Study | Return to List | Next Study

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk
ClinicalTrials.gov Identifier:
NCT00956345
First received: August 10, 2009
Last updated: July 4, 2012
Last verified: June 2012
History of Changes
  Purpose

This trial is conducted in Europe, Japan and the United States of America (USA).

The aim of this clinical trial is to investigate the safety and pharmacokinetics (the determination of the concentration of the administered medication in blood over time) of Pegylated Recombinant Factor IX in Non-Bleeding Patients with Haemophilia B.


Condition Intervention Phase
Congenital Bleeding Disorder
Haemophilia B
 Drug: 40K PEG-rFIX
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Centre, Multi-National, Open-Label, Dose Escalation Trial Evaluating Safety and Pharmacokinetics of Ascending Intravenous Doses of 40K Pegylated Recombinant FIX in Non-Bleeding Patients With Haemophilia B.

Resource links provided by NLM:

Drug Information available for: Factor IX
U.S. FDA Resources

Further study details as provided by Novo Nordisk:

Primary Outcome Measures:
  • Frequency of Adverse Events (AEs), Serious Adverse Events (SAEs) and Medical Events of Special Interests (MESIs) reported during the trial period [ Time Frame: assessed up to five weeks after trial product administration ] [ Designated as safety issue: Yes ]
  • Antibody formation against 40K PEG-rFIX and test for inhibitors (Bethesda) [ Time Frame: assessed up to five weeks after trial product administration ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • AUC, CL, T½, Incremental recovery (first sample) from 0 to 48 hours after trial product administration [ Time Frame: assessed up to five weeks after trial product administration ] [ Designated as safety issue: No ]
  • AUC, CL, T½, Incremental recovery (first sample) from 0 to 168 hours after trial product administration [ Time Frame: assessed up to five weeks after trial product administration ] [ Designated as safety issue: No ]

Enrollment: 18
Study Start Date: August 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: 40K PEG-rFIX
Cohort to receive a single dose of 25U/kg 40K PEG-rFIX administered intravenously (into the vein)
Experimental: B Drug: 40K PEG-rFIX
Cohort to receive a single dose of 50U/kg 40K PEG-rFIX administered intravenously (into the vein)
Experimental: C Drug: 40K PEG-rFIX
Cohort to receive a single dose of 100U/kg 40K PEG-rFIX administered intravenously (into the vein)

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with haemophilia B (baseline level of Factor IX less than or equal to 2%)
  • History of at least 150 exposure days to any Factor IX products
  • Body Mass Index (BMI) below 30.0 kg/m2 (inclusive)

Exclusion Criteria:

  • History of Factor IX inhibitors
  • Platelet count less than 50,000 platelets/microlitre (assessed by laboratory)
  • Kidney or liver dysfunction
  • Scheduled surgery requiring Factor IX replacement therapy, during the trial period
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00956345

Locations
United States, Oregon
Novo Nordisk Clinical Trial Call Center
Portland, Oregon, United States, 97239
United States, Virginia
Novo Nordisk Clinical Trial Call Center
Richmond, Virginia, United States, 23219
France
Lyon, France, 69003
Germany
Berlin, Germany, 10249
Japan
Kashihara-shi, Nara, Japan, 634 8522
Spain
Madrid, Spain, 28046
United Kingdom
Oxford, United Kingdom, OX3 7LJ
Sponsors and Collaborators
Novo Nordisk
Investigators
Study Director: Karin Knobe, MD Novo Nordisk
  More Information

Additional Information:
Clinical Trials at Novo Nordisk  This link exits the ClinicalTrials.gov site

No publications provided by Novo Nordisk

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Novo Nordisk
ClinicalTrials.gov Identifier: NCT00956345     History of Changes
Other Study ID Numbers: NN7999-3639, 2009-011085-28, 090857
Study First Received: August 10, 2009
Last Updated: July 4, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Germany: Paul-Ehrlich-Institut
Spain: Ministry of Health
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Japan: Ministry of Health, Labor and Welfare
United States: Food and Drug Administration

Additional relevant MeSH terms:
Hemophilia B
Hemophilia A
Blood Coagulation Disorders
Hemostatic Disorders
Hemorrhagic Disorders
Hemorrhage
Hematologic Diseases
 Vascular Diseases
Cardiovascular Diseases
Blood Coagulation Disorders, Inherited
Coagulation Protein Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013